Changeflow GovPing Healthcare Regulation FDA Complaint Document
Priority review Consultation Added Consultation

FDA Complaint Document

Favicon for www.regulations.gov Regs.gov: Food and Drug Administration
Published March 13th, 2026
Detected March 15th, 2026
Email

Summary

The FDA has posted a complaint document related to FDA-2026-H-2191-0001. This document is open for public comment, with a deadline for submissions.

What changed

The U.S. Food and Drug Administration (FDA) has released a complaint document, identified by docket number FDA-2026-H-2191-0001, for public review and comment. The document, authored by CTP, is available for download and is currently in a consultation phase.

Regulated entities, particularly drug manufacturers and pharmaceutical companies, should review this complaint document to understand potential regulatory concerns or policy discussions. Interested parties are encouraged to submit comments by the specified deadline to influence any potential future regulatory actions or guidance. Failure to submit comments may result in the FDA proceeding without considering specific industry feedback.

What to do next

  1. Review the FDA complaint document FDA-2026-H-2191-0001
  2. Submit comments by the specified deadline

Source document (simplified)

Content

There are no documents available to view or download

Attachments 1

Complaint

More Information
- Author(s) CTP
Download

Classification

Agency
Various Federal Agencies
Published
March 13th, 2026
Instrument
Consultation
Legal weight
Non-binding
Stage
Consultation
Change scope
Substantive

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies Healthcare providers
Geographic scope
National (US)

Taxonomy

Primary area
Healthcare
Operational domain
Compliance
Topics
Pharmaceuticals Public Health

Get Healthcare Regulation alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.